Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;21(6):916-925.
doi: 10.1038/s41589-025-01881-9. Epub 2025 Apr 29.

Facile generation of drug-like conformational antibodies specific for amyloid fibrils

Affiliations

Facile generation of drug-like conformational antibodies specific for amyloid fibrils

Alec A Desai et al. Nat Chem Biol. 2025 Jun.

Abstract

Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer's disease) and α-synuclein fibrils (Parkinson's disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.

PubMed Disclaimer

Conflict of interest statement

Competing interests: P.M.T. is a member of the scientific advisory boards for Nabla Bio, Aureka Biotechnologies and Dualitas Therapeutics. The remaining authors declare no competing interests.

Update of

Similar articles

References

    1. Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife 7, e34317 (2018). - PubMed - PMC - DOI
    1. Peng, C. et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 557, 558–563 (2018). - PubMed - PMC - DOI
    1. Combs, B., Hamel, C. & Kanaan, N. M. Pathological conformations involving the amino terminus of tau occur early in Alzheimer’s disease and are differentially detected by monoclonal antibodies. Neurobiol. Dis. 94, 18–31 (2016). - PubMed - PMC - DOI
    1. Covell, D. J. et al. Novel conformation-selective α-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson’s disease. Neuropathol. Appl. Neurobiol. 43, 604–620 (2017). - PubMed - PMC - DOI
    1. Kanaan, N. M. et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 31, 9858–9868 (2011). - PubMed - PMC - DOI

LinkOut - more resources